Evidence map›Paper›PMID 28560782›Full record

Trial reportEuropean journal of heart failure2017

Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.

John R Teerlink, Marco Metra, Gerasimos S Filippatos, Beth A Davison, Jozef Bartunek, Andre Terzic, Bernard J Gersh, Thomas J Povsic, Timothy D Henry, Bertrand Alexandre and 6 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of heart failure, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Highlights in heart failure.ESC heart failure · 2019
    Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Stem Cell Therapy in Ischemic Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Cell Therapy in the Treatment of Coronary Heart Disease.International journal of molecular sciences · 2023
    Review
  17. Article
  18. Article
  19. Mesenchymal STRO-1/STRO-3Future cardiology · 2023
    Review
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

John R TeerlinkSchool of Medicine, University of California San Francisco and Section of Cardiology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.
Marco MetraCardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University and Spedali Civili, Brescia, Italy.
Gerasimos S FilippatosNational and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece.
Beth A DavisonMomentum Research, Inc., Durham, NC, USA.
Jozef BartunekCardiovascular Centre, OLV Hospital, Aalst, Belgium.
Andre TerzicDepartment of Cardiovascular Diseases, Mayo Clinic, Center for Regenerative Medicine, Rochester, MN, USA.
Bernard J GershDepartment of Cardiovascular Diseases, Mayo Clinic, Center for Regenerative Medicine, Rochester, MN, USA.
Thomas J PovsicDuke Clinical Research Institute and Duke Medicine, Durham, NC, USA.
Timothy D HenryCedars Sinai Heart Institute, Los Angeles, CA, USA.
Bertrand AlexandreCelyad, Mont Saint Guibert, Belgium.
Christian HomsyCelyad, Mont Saint Guibert, Belgium.
Christopher EdwardsMomentum Research, Inc., Durham, NC, USA.
Aymeric SeronCelyad, Mont Saint Guibert, Belgium.
William WijnsCardiovascular Centre, OLV Hospital, Aalst, Belgium.
Gad CotterMomentum Research, Inc., Durham, NC, USA.
CHART Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsLeft ventricular (LV) reverse remodelling is an important marker of improved outcomes in patients with advanced heart failure (HF). We examined the impact of the intramyocardial administration of bone-marrow-derived, lineage-directed, autologous cardiopoietic mesenchymal stem cells (C3BS-CQR-1) on LV remodelling in patients with advanced HF enrolled in the CHART-1 study. METHODS AND

resultsPatients (n=351) with symptomatic advanced HF secondary to ischaemic heart disease, and reduced LV ejection fraction (LVEF <35%) were randomized to receive C3BS-CQR-1 or a sham procedure. In a post hoc analysis we examined the effect of C3BS-CQR-1 on LV reverse remodelling within 1 year of the procedure and the influence of C3BS-CQR-1 dosing in the 271 patients treated as randomized. Delivery of C3BS-CQR-1 was associated with a progressive decrease in both LV end-diastolic volume (LVEDV) and end-systolic volume (LVESV) within 52 weeks after treatment. At 1 year, the LVEDV and LVESV of treated patients decreased by 17.0 mL and 12.8 mL greater than controls (P=0.006 and P=0.017, respectively). The effect on LVEDV was maintained after multivariable adjustment for baseline age, systolic blood pressure, LVEDV, LVEF and history of myocardial infarction. The largest reverse remodelling was evident in the patients receiving a moderate number of injections (<20).

conclusionIn CHART-1, intramyocardial administration of cardiopoietic stem cells led to reverse remodelling as evidenced by significant progressive decreases in LVEDV and LVESV through the 52 weeks of follow-up. Further studies are needed to explore the dose response with regard to cell number and injected volume, and reverse remodelling.

Indexed as

FemaleGenetic TherapyHeart FailureHumansMaleMesenchymal Stem Cell TransplantationMiddle AgedStroke VolumeTreatment OutcomeVentricular Function, LeftVentricular RemodelingHeart failureRemodellingStem cells

Identifiers

PMID28560782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.